Literature DB >> 20057312

Late diagnosis in the HAART era: proposed common definitions and associations with mortality.

Caroline A Sabin, Achim Schwenk, Margaret A Johnson, Brian Gazzard, Martin Fisher, John Walsh, Chloe Orkin, Teresa Hill, Richard Gilson, Kholoud Porter, Philippa Easterbrook, Valerie Delpech, Loveleen Bansi, Clifford Leen, Mark Gompels, Jane Anderson, Andrew N Phillips.   

Abstract

OBJECTIVE: To identify a definition of presentation after clinical or immunological disease progression that will reliably identify an individual at high risk of mortality over the first 3 months after HIV diagnosis and that can be adopted as a basis for comparing over time and regions.
DESIGN: An observational cohort study.
METHODS: Individuals seen for the first time at a UK Collaborative HIV Cohort study clinic from 1996 to 2006 were identified. Two immunological (CD4 cell count < 200 cells/microl and CD4 cell count <50 cells/microl) and two clinical (AIDS and severe/moderate AIDS) criteria for presentation with advanced HIV disease were compared, as well as combinations of them. The predictive ability of each diagnosis for identifying individuals who died in the first 3 months after HIV diagnosis was assessed.
RESULTS: Fifteen thousand seven hundred and seventy-four patients were included, of whom 1495 (9.5%), 4231 (26.8%), 1523 (9.7%) and 379 (2.4%) had a CD4 cell count below 50 cells/microl, CD4 cell count below 200 cells/microl, AIDS or severe/moderate AIDS at diagnosis; CD4 cell counts were unavailable for 2264 (14.4%) patients. Two hundred and six (1.3%) patients died within the first 3 months. Sensitivities of the individual criteria ranged from 18.0% (severe/moderate AIDS) to 50.5% (CD4 cell count < 200 cells/microl) with specificities ranging from 73.5% (CD4 < 200 cells/microl) to 97.8% (severe/moderate AIDS). Combinations of clinical and immunological criteria increased the sensitivity but decreased the specificity.
CONCLUSION: We propose that presentation with 'advanced HIV disease' is presentation with a CD4 cell count below 200 cells/microl or AIDS, whereas 'late' presentation is defined as presentation when the CD4 cell count is below that when treatment should be initiated (currently CD4 cell count < 350 cells/microl or AIDS).

Entities:  

Mesh:

Year:  2010        PMID: 20057312     DOI: 10.1097/QAD.0b013e328333fa0f

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  32 in total

1.  Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.

Authors:  Caroline E Sloan; Karen Champenois; Philippe Choisy; Elena Losina; Rochelle P Walensky; Bruce R Schackman; Faiza Ajana; Hugues Melliez; A D Paltiel; Kenneth A Freedberg; Yazdan Yazdanpanah
Journal:  AIDS       Date:  2012-01-02       Impact factor: 4.177

2.  Feasibility of a Home-Based Speed of Processing Training Program in Middle-Aged and Older Adults With HIV.

Authors:  Shameka L Cody; Pariya L Fazeli; David E Vance
Journal:  J Neurosci Nurs       Date:  2015-08       Impact factor: 1.230

3.  Trends in the spectrum of engagement in HIV care and subsequent clinical outcomes among men who have sex with men (MSM) at a Boston community health center.

Authors:  Jordan E Axelrad; Matthew J Mimiaga; Chris Grasso; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2013-05       Impact factor: 5.078

4.  Trends of HIV-1 incidence with credible intervals in Sweden 2002-09 reconstructed using a dynamic model of within-patient IgG growth.

Authors:  Ethan Obie Romero-Severson; Cody Lee Petrie; Edward Ionides; Jan Albert; Thomas Leitner
Journal:  Int J Epidemiol       Date:  2015-07-10       Impact factor: 7.196

5.  Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.

Authors:  Rebecca K Lodwick; Caroline A Sabin; Kholoud Porter; Bruno Ledergerber; Ard van Sighem; Alessandro Cozzi-Lepri; Pavel Khaykin; Amanda Mocroft; Lisa Jacobson; Stephane De Wit; Niels Obel; Antonella Castagna; Jan-Christian Wasmuth; John Gill; Marina B Klein; Stephen Gange; Melchor Riera; Cristina Mussini; Félix Gutiérrez; Giota Touloumi; Patrizia Carrieri; Jodie L Guest; Norbert H Brockmeyer; Andrew N Phillips
Journal:  Lancet       Date:  2010-07-15       Impact factor: 79.321

6.  Twelve months of routine HIV screening in 6 emergency departments in the Paris area: results from the ANRS URDEP study.

Authors:  Enrique Casalino; Bruno Bernot; Olivier Bouchaud; Chakib Alloui; Christophe Choquet; Elisabeth Bouvet; Florence Damond; Sandra Firmin; Aurore Delobelle; Beatrice Ename Nkoumazok; Guillaume Der Sahakian; Jean-Paul Viard; Olivier Zak Dit Zbar; Elisabeth Aslangul; Anne Krivine; Julie Zundel; Jade Ghosn; Patrice Nordmann; Yann-Erick Claessens; Tassadit Tahi; Bruno Riou; Agnès Gautheret-Dejean; Christine Katlama; Pierre Hausfater; Françoise Brun-Vézinet; Dominique Costagliola
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

7.  Time trends and correlates of late presentation for HIV care in Northern Greece during the decade 2000 to 2010.

Authors:  Simeon Metallidis; Dimitrios Pilalas; Lemonia Skoura; Anna-Bettina Haidich; Olga Tsachouridou; Maria Papaioannou; Theofilos Chrysanthidis; Isidora Bakaimi; Zoe A Antoniadou; Apostolia Margariti; Nicolaos Malisiovas; Pavlos Nikolaidis
Journal:  J Int AIDS Soc       Date:  2012-10-11       Impact factor: 5.396

8.  When to start antiretroviral therapy: the need for an evidence base during early HIV infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred M Gordin; Álvaro H Borges; James D Neaton
Journal:  BMC Med       Date:  2013-06-14       Impact factor: 8.775

9.  Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study.

Authors:  Karen Champenois; Anthony Cousien; Lise Cuzin; Stéphane Le Vu; Sylvie Deuffic-Burban; Emilie Lanoy; Karine Lacombe; Olivier Patey; Pascal Béchu; Marcel Calvez; Caroline Semaille; Yazdan Yazdanpanah
Journal:  BMC Infect Dis       Date:  2013-05-02       Impact factor: 3.090

10.  Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study).

Authors:  Ann K Sullivan; Dorthe Raben; Joanne Reekie; Michael Rayment; Amanda Mocroft; Stefan Esser; Agathe Leon; Josip Begovac; Kees Brinkman; Robert Zangerle; Anna Grzeszczuk; Anna Vassilenko; Vesna Hadziosmanovic; Maksym Krasnov; Anders Sönnerborg; Nathan Clumeck; José Gatell; Brian Gazzard; Antonella d'Arminio Monforte; Jürgen Rockstroh; Jens D Lundgren
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.